The Food and Drug Administration approved an update to MannKind Corp.'s (Nasdaq: MNKD) Afrezza prescribing information. The stock price gained 48 cents to close at $2.82.
FDA approves update to MannKind's Afrezza
October 03, 2017 at 18:20 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.